Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors (Q35851786)

10 August 2017

1 reference

title

Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors (English)

1 reference

10 August 2017

0 references

Stanley Plotkin

1 reference

10 August 2017

Genoveffa Franchini

1 reference

10 August 2017

Sanjay Gurunathan

series ordinal

1 reference

10 August 2017

Lynn Baglyos

series ordinal

1 reference

10 August 2017

Jim Tartaglia

series ordinal

1 reference

10 August 2017

publication date

1 August 2004

1 reference

Expert Review of Vaccines

10 August 2017

published in

1 reference

10 August 2017

1 reference

10 August 2017

issue

4 Suppl

1 reference

10 August 2017

page(s)

S75-88

1 reference

Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S75

NYVAC: a highly attenuated strain of vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S75

Applications of pox virus vectors to vaccination: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S75

Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S75

Fowlpox virus host range restriction: gene expression, DNA replication, and morphogenesis in nonpermissive mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S75

Efficacy of a canarypox virus-vectored vaccine against feline leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S75

Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S75

Immunoprophylaxis to prevent mother-to-child transmission of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S75

Mucosal immunization with PLGA-microencapsulated DNA primes a SIV-specific CTL response revealed by boosting with cognate recombinant modified vaccinia virus Ankara

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S75

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S75

Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S75

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S75

Vaccination with Rev and Tat against AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S75

Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S75

Response to smallpox vaccine in persons immunized in the distant past

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S75

Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S75

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S75

Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S75

Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S75

Cytokine responses to human immunodeficiency virus type 1 (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1(SF-2) recombinant GP120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S75

What can be achieved with an HIV vaccine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S75

Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S75

21 January 2018

Identifiers

DOI

10.1586/14760584.3.4.S75

1 reference

10 August 2017

1 reference